Market Overview - The animal health sector experienced a decline of 0.32% on January 23, with BioShares leading the drop [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (920275) with a closing price of 9.68, up 4.09% on a trading volume of 36,300 shares and a turnover of 34.72 million yuan [1] - Haili Biological (603718) closed at 6.55, up 1.24% with a trading volume of 95,100 shares and a turnover of 61.91 million yuan [1] - Deyu Biological (920970) closed at 8.44, up 1.20% with a trading volume of 19,200 shares and a turnover of 16.26 million yuan [1] - Conversely, BioShares (600201) closed at 17.35, down 1.42% with a trading volume of 315,700 shares and a turnover of 551 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 142 million yuan from institutional investors, while retail investors experienced a net inflow of 124 million yuan [2][3] - Specific stock capital flows included: - Zhongmu Shares (600195) with a net inflow of 14.27 million yuan from institutional investors [3] - Qudongli (920275) had a net inflow of 2.44 million yuan from retail investors [3] - Deyu Biological (920970) faced a net outflow of 1.04 million yuan from institutional investors [3]

Core Viewpoint - The company announced that the government of Lanzhou City will expropriate certain idle assets from its subsidiary, Lanzhou Biopharmaceutical Factory, and its wholly-owned subsidiary, Lanzhou Zhongmu Pharmaceutical and Medical Technology Co., Ltd., with a total amount of 228.9782 million yuan [1] Group 1 - The expropriation involves an amount of 228.9782 million yuan [1] - As of January 23, 2026, the company has received compensation of 145 million yuan and is urging the government to pay the remaining amount [1] - This transaction does not constitute a related party transaction or a major asset restructuring, and the financial impact will be based on the audited data for 2025 [1]

证券日报网讯1月22日，瑞普生物（300119）在互动平台回答投资者提问时表示，未来公司将持续深耕 该领域，丰富产品矩阵，为宠物提供更多优质的健康解决方案。 ...

证券日报网讯 1月22日，瑞普生物在互动平台回答投资者提问时表示，公司应收账款按与客户签订的合 同约定回款期推进回款工作，公司已严格按照账龄分析法及单项认定法计提坏账准备，相关财务处理符 合企业会计准则要求，充分考虑了回款相关风险。具体情况请关注公司后续披露的定期报告。 （文章来源：证券日报） ...

Core Viewpoint - The animal health sector experienced a slight increase of 0.54% on January 22, with Xianfeng Holdings leading the gains. The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the Shenzhen Component Index increased by 0.5% to 14327.05 [1]. Group 1: Stock Performance - Xianfeng Holdings (002141) closed at 4.19, up 9.97% with a trading volume of 720,300 shares and a transaction value of 297 million yuan [1]. - Other notable performers include Biological Shares (600201) at 17.60, up 1.79%, and Zhongmu Shares (600195) at 8.54, also up 1.79% [1]. - The overall trading volume and transaction values for various stocks in the animal health sector indicate active market participation [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 73.79 million yuan from institutional investors, while retail investors experienced a net outflow of 27.83 million yuan [2]. - The main capital inflow was primarily directed towards Xianfeng Holdings, which attracted 121 million yuan from institutional investors, representing 40.71% of its trading volume [3]. - Other stocks like Jinhe Biological (002688) and *ST Green Health (002868) also saw varying degrees of net inflow and outflow from different investor categories [3].

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：现在家庭对宠物陪伴特别看重，贵公司是否会推出一 些宠物保健品或者营养品，提升宠物的体质健康和营养均衡。 瑞普生物（300119.SZ）1月22日在投资者互动平台表示，公司已推出氨糖软骨素、角鲨烯辅酶 Q10等多 款宠物营养保健品，26年即将上市磷虾鱼油、益生菌等产品，可助力宠物体质提升与营养均衡，契合养 宠家庭的宠物健康养护需求。未来公司将持续深耕该领域，丰富产品矩阵，为宠物提供更多优质的健康 解决方案。 ...

Core Viewpoint - The animal health sector experienced a decline of 0.65% on January 21, with Huisheng Biological leading the drop. The Shanghai Composite Index rose by 0.08%, while the Shenzhen Component Index increased by 0.7 [1] Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Shunlian Biological up by 4.20% and Huisheng Biological down by 6.19% [1][2] - The trading volume for Huisheng Biological was 419,900 shares, with a transaction value of 1.192 billion yuan, indicating significant market activity despite the decline [2] Group 2: Capital Flow - The animal health sector saw a net inflow of 9.6935 million yuan from institutional investors, while retail investors experienced a net outflow of 73.8174 million yuan, suggesting a shift in investor sentiment [2][3] - Among individual stocks, Xianfeng Holdings had a net inflow of 15.1182 million yuan from institutional investors, while Huisheng Biological saw a net outflow of 42.2249 million yuan from retail investors [3]

金河生物公告称，2021年公司非公开发行股票，实际募集资金净额8.02亿元。"生产工艺系统降耗增效 改造项目"已基本建设完成，公司对该募投项目结项，将节余募集资金232.77万元（含利息收入）永久 补充流动资金，募投项目未支付款项由自有资金支付。近日，公司注销该项目募集资金专户（开户行： 中国民生银行呼和浩特分行；账号：633142845），相关《募集资金三方监管协议》相应终止。 ...

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., forecasts a significant increase in net profit for the year 2025, with expectations of a rise between 89.64% and 110.11% compared to the previous year [2][3]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company to be between 176 million to 195 million yuan for 2025, representing an increase of 83.19 million to 102.19 million yuan year-on-year [2][3]. - The forecasted net profit, excluding non-recurring gains and losses, is expected to be between 137 million to 153 million yuan, reflecting a year-on-year increase of 70.19% to 90.07% [2][3]. Group 2: Previous Year’s Performance - In the previous year, the net profit attributable to shareholders of the parent company was 92.81 million yuan, and the net profit after excluding non-recurring gains and losses was 80.50 million yuan [5]. Group 3: Reasons for Performance Increase - The introduction of new products, such as the avian adenovirus series vaccine, has contributed to the company's growth. Additionally, the pet sector has seen rapid development through enhanced channel building and brand development [7]. - The company is focusing on marketing system reforms, controlling sales expenses, and optimizing production processes and procurement management to reduce production costs, demonstrating strong operational resilience [7].

证券之星消息，1月20日动物保健板块较上一交易日下跌0.01%，生物股份领跌。当日上证指数报收于 4113.65，下跌0.01%。深证成指报收于14155.63，下跌0.97%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300871 | 回盛生物 | 31.49 | 11.83% | 38.34万 | | 11.69 乙 | | 603566 | 普莱柯 | 13.36 | 1.06% | 5.21万 | | 6961.35万 | | 300119 | 瑞普生物 | 20.55 | 0.98% | 1 6.64万 | | 1.36亿 | | 920275 | 驱动力 | 9.35 | 0.75% | 2.23万 | | 2072.97万 | | 600195 | 中牧股份 | 8.54 | 0.59% | 38.73万 | | 3.32亿 | | 603718 | 海利生物 | 6.46 | 0.00% | 7.53万 | | 4860.40万 ...